Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future medicines to market.

A long-acting flea and tick treatment from Merck Animal Health has earned approval for dogs at least six months old from the ...

Merck opened a $1 billion facility at its North Carolina site last month to boost U.S. production. Merck to invest $1 billion in new Delaware plant to boost US manufacturing Skip to main content ...

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware Apr. 29, 2025 6:45 AM ET Merck & Co., Inc. (MRK) Q1: 2025-04-24 Earnings Summary ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the ...

The Delaware Supreme Court ruled in favor of Bayer regarding lawsuits associated with talc-based foot powder products. Bayer acquired the foot powder products from Merck in a $14.2 billion deal in ...

Merck is seeking confirmation that Bayer is liable for talc claims that have been filed against both companies since 2014, when Bayer bought product lines from Merck in a $14 billion deal. The ...